WO2016209959A3 - Combinaisons de peptides et leur utilisation dans le traitement de l'allergie aux pollen de cèdre - Google Patents

Combinaisons de peptides et leur utilisation dans le traitement de l'allergie aux pollen de cèdre Download PDF

Info

Publication number
WO2016209959A3
WO2016209959A3 PCT/US2016/038760 US2016038760W WO2016209959A3 WO 2016209959 A3 WO2016209959 A3 WO 2016209959A3 US 2016038760 W US2016038760 W US 2016038760W WO 2016209959 A3 WO2016209959 A3 WO 2016209959A3
Authority
WO
WIPO (PCT)
Prior art keywords
cry
peptide combinations
cell epitope
japanese cedar
epitope peptide
Prior art date
Application number
PCT/US2016/038760
Other languages
English (en)
Other versions
WO2016209959A2 (fr
Inventor
Claus Lundegaard
Peter Sejer Andersen
Alessandro Sette
Bjoern Peters
Veronique SCHULTEN
John Sidney
Lars Harder CHRISTENSEN
Original Assignee
Alk-Abelló A/S
La Jolla Institute For Allergy And Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alk-Abelló A/S, La Jolla Institute For Allergy And Immunology filed Critical Alk-Abelló A/S
Publication of WO2016209959A2 publication Critical patent/WO2016209959A2/fr
Publication of WO2016209959A3 publication Critical patent/WO2016209959A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des combinaisons peptidiques pour une utilisation en immunothérapie pour le traitement de l'allergie au pollen de cyprès et de cèdre, par exemple du pollen du cèdre japonais et du pollen à réaction croisée associés de membres de la famille des cyprès (Cupressaceae). Les combinaisons peptidiques, qui sont conçue de façon à avoir une grande couverture HLA dans le monde entier, comprennent au moins trois peptides différents, comprenant au moins un peptide Cry j 1 et au moins un peptide Cry j 2.
PCT/US2016/038760 2015-06-22 2016-06-22 Combinaisons de peptides et leur utilisation dans le traitement de l'allergie aux pollen de cèdre WO2016209959A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562182883P 2015-06-22 2015-06-22
US62/182,883 2015-06-22

Publications (2)

Publication Number Publication Date
WO2016209959A2 WO2016209959A2 (fr) 2016-12-29
WO2016209959A3 true WO2016209959A3 (fr) 2017-02-09

Family

ID=56404306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/038760 WO2016209959A2 (fr) 2015-06-22 2016-06-22 Combinaisons de peptides et leur utilisation dans le traitement de l'allergie aux pollen de cèdre

Country Status (1)

Country Link
WO (1) WO2016209959A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201601872D0 (en) * 2016-02-02 2016-03-16 Circassia Ltd Japanese cedar and japanese cypress peptides for preventing or treating allergy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152927A1 (en) * 1991-07-12 2005-07-14 Immulogic Pharmaceutical Corp. Allergenic proteins and peptides from Japanese cedar pollen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0756629A1 (fr) 1994-04-08 1997-02-05 Immunologic Pharmaceutical Corporation Formulations pharmaceutiques utilisees dans le traitement de la pollinose du cedre du japon
TW438807B (en) 1994-09-10 2001-06-07 Hayashibara Biochem Lab Novel peptides containing T-cell epitope(s) of cedar pollen allergens, the processes therefor and the pharmaceutical uses thereof
CN1227566A (zh) 1996-06-14 1999-09-01 明治乳业株式会社 T细胞表位肽
CA2546443A1 (fr) 2003-11-18 2005-06-02 Nanopass Technologies Ltd. Systeme de penetration ameliore et procede permettant de faire coulisser des micro-aiguilles
WO2006054280A2 (fr) 2004-11-18 2006-05-26 Nanopass Technologies Ltd. Systeme et procede pour administrer un fluide a une barriere biologique souple
JP2010512170A (ja) 2005-12-08 2010-04-22 ナノパス テクノロジーズ エルティディ． 薬剤投与器用マイクロ・ニードル・アダプタ
US20130110043A1 (en) 2011-10-26 2013-05-02 Nanopass Technologies Ltd. Microneedle Intradermal Drug Delivery Device with Auto-Disable Functionality
US20140350514A1 (en) 2013-05-22 2014-11-27 Nanopass Technologies Ltd. Systems and methods for intradermal delivery of therapeutics using microneedles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152927A1 (en) * 1991-07-12 2005-07-14 Immulogic Pharmaceutical Corp. Allergenic proteins and peptides from Japanese cedar pollen

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ANDREATTA MASSIMO ET AL: "Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 67, no. 11, 29 September 2015 (2015-09-29), pages 641 - 650, XP035870215, ISSN: 0093-7711, [retrieved on 20150929], DOI: 10.1007/S00251-015-0873-Y *
DENISE M. MCKINNEY ET AL: "A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population - Online Supplemental Material", IMMUNOGENETICS, 1 May 2013 (2013-05-01), pages Supp.1-3, XP055305849, Retrieved from the Internet <URL:https://static-content.springer.com/esm/art:10.1007/s00251-013-0684-y/MediaObjects/251_2013_684_MOESM1_ESM.pdf> [retrieved on 20160927], DOI: 10.1007/s00251-013-0684-y *
FUMIO TAKAIWA ET AL: "Development of a rice-based peptide vaccine for Japanese cedar and cypress pollen allergies", TRANSGENIC RESEARCH, vol. 23, no. 4, 1 August 2014 (2014-08-01), NL, pages 573 - 584, XP055305863, ISSN: 0962-8819, DOI: 10.1007/s11248-014-9790-3 *
HIRAHARA K ET AL: "Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 108, no. 1, 1 July 2001 (2001-07-01), pages 94 - 100, XP002579821, ISSN: 0091-6749, DOI: 10.1067/MAI.2001.115481 *
J. SIDNEY ET AL: "Five HLA-DP Molecules Frequently Expressed in the Worldwide Human Population Share a Common HLA Supertypic Binding Specificity", THE JOURNAL OF IMMUNOLOGY, vol. 184, no. 5, 5 February 2010 (2010-02-05), US, XP055306325, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0903655 *
KAROSIENE EDITA ET AL: "NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 65, no. 10, 31 July 2013 (2013-07-31), pages 711 - 724, XP035332584, ISSN: 0093-7711, [retrieved on 20130731], DOI: 10.1007/S00251-013-0720-Y *
MASAKO TSUNEMATSU ET AL: "Effect of Cry-consensus Peptide, a Novel Recombinant Peptide for Immunotherapy of Japanese Cedar Pollinosis, on an Experimental Allergic Rhinitis Model in B10.S Mice", ALLERGOLOGY INTERNATIONAL, vol. 56, no. 4, 1 January 2007 (2007-01-01), JP, pages 465 - 472, XP055306138, ISSN: 1323-8930, DOI: 10.2332/allergolint.O-07-495 *
MCKINNEY DENISE M ET AL: "A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 65, no. 5, 8 February 2013 (2013-02-08), pages 357 - 370, XP035332566, ISSN: 0093-7711, [retrieved on 20130208], DOI: 10.1007/S00251-013-0684-Y *
SONE T ET AL: "IDENTIFICATION OF HUMAN T CELL EPITOPES IN JAPANESE CYPRESS POLLEN ALLERGEN, CHA O 1, ELUCIDATES THE INTRINSIC MECHANISM OF CROSS-ALLERGENICITY BETWEEN CHA O 1 AND CRY J 1, THE MAJOR ALLERGEN OF JAPANESE CEDAR POLLEN, AT THE T CELL LEVEL", CLINICAL & EXPERIMENTAL ALLERGY, vol. 35, no. 5, 1 May 2005 (2005-05-01), pages 664 - 671, XP009082518, ISSN: 0954-7894, DOI: 10.1111/J.1365-2222.2005.02221.X *
SONE T ET AL: "T cell epitopes in Japanese cedar (Cryptomeria japonica) pollen allergens: Choice of major T cell epitopes in Cry j 1 and Cry j 2 toward design of the peptide-based immunotherapeutics for the management of Japanese cedar pollinosis", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 161, no. 1, 1 January 1998 (1998-01-01), pages 448 - 457, XP002579823, ISSN: 0022-1767 *
SONE TOSHIO ET AL: "Peptide specificity, HLA class II restriction, and T-cell subsets of the T-cell clones specific to either Cry j 1 or Cry j 2, the major allergens of Japanese cedar (Cryptomeria japonica) pollen", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 119, no. 3, July 1999 (1999-07-01), pages 185 - 196, XP009191847, ISSN: 1018-2438 *
WANG PENG ET AL: "Peptide binding predictions for HLA DR, DP and DQ molecules", BMC BIOINFORMATICS, BIOMED CENTRAL, LONDON, GB, vol. 11, no. 1, 22 November 2010 (2010-11-22), pages 568, XP021085842, ISSN: 1471-2105, DOI: 10.1186/1471-2105-11-568 *

Also Published As

Publication number Publication date
WO2016209959A2 (fr) 2016-12-29

Similar Documents

Publication Publication Date Title
MX2023001403A (es) Neoantigenos y metodos de su uso.
WO2016191643A3 (fr) Agents de liaison à tigit et leurs utilisations
WO2015197823A3 (fr) Anticorps et fragments de liaison à l&#39;antigène qui se lient spécifiquement à la protéine tau associée aux microtubules
ZA201904725B (en) Personalised immunogenic peptide identification platform
WO2014113490A3 (fr) Peptides wt-1 immunogènes et leurs procédés d&#39;utilisation
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
WO2015134722A3 (fr) Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs
WO2016033225A3 (fr) Anticorps, compositions et leurs utilisations
MX366588B (es) Cadena j modificada.
WO2015117008A3 (fr) Anticorps anti-vih de neutralisation large et épitope associé
EP4324481A3 (fr) Anticorps antagonistes dirigés contre un peptide associé au gène de la calcitonine et leurs procédés d&#39;utilisation
WO2016149613A3 (fr) Peptides de liaison à mcl-1 sélectifs
WO2016086175A8 (fr) Anticorps anti-cd32a déficients en effecteur
WO2017049038A3 (fr) Anticorps anti-cd115
WO2015112558A3 (fr) Peptides, dispositifs et procédés pour la détection d&#39;anticorps d&#39;anaplasma
MX2016008305A (es) Combinaciones de peptidos y usos de los mismos en tratar alergia al acaro del polvo.
HK1254818A1 (zh) 抗原肽及其用於診斷和治療自閉症的用途
WO2016020882A3 (fr) Anticorps de type angiopoétine 4 (angptl4) et procédés d&#39;utilisation
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
WO2017040329A3 (fr) Peptides se liant à bfl -1
HK1259067A1 (zh) 用牛免疫缺陷病毒gag蛋白的重組病毒樣顆粒
WO2017019957A3 (fr) Protéines de liaison et leurs procédés d&#39;utilisation
WO2016016651A3 (fr) Traitement et prévention du paludisme
WO2015057966A3 (fr) Thérapies, vaccins, et procédés prédictifs pour les virus du syndrome respiratoire du moyen-orient (mers-cov)
WO2016209959A3 (fr) Combinaisons de peptides et leur utilisation dans le traitement de l&#39;allergie aux pollen de cèdre

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16736967

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16736967

Country of ref document: EP

Kind code of ref document: A2